539 results about "Cell Membrane Proteins" patented technology

The invention discloses a lysosome targeted chimera based on Sortilin and application thereof. The lysosome targeted chimera comprises a ligand molecule of a lysosome targeted receptor and a ligand molecule of a targeted protein to be degraded, wherein the ligand molecule and the ligand molecule are connected through a linker; the lysosome targeting receptor is Sortilin, and the ligand molecule of the lysosome targeting receptor is a polypeptide targeting the Sortilin; the protein to be degraded is membrane protein or extracellular protein. Furthermore, the polypeptide of the targeted Sortilin is connected with an enzyme response sequence and an integrin receptor targeting sequence. According to the invention, the Sortilin-combined ligand neurotensin is functionally coupled with the neutralizing antibody or polypeptide of overexpression protein in targeted tumor or inflammatory diseases, and the Sortilin-combined ligand neurotensin has obvious treatment gain in malignant solid tumor and psoriasis models. The discovery promotes the transformation potential of the lysosome participating in the biological agent, and provides a dual strategy for realizing accurate degradation through receptor recruitment and microenvironment induction.

The invention discloses a fermentation method of recombinant bacillus subtilis for expressing vibrio parahaemolyticus outer membrane protein, which comprises the following steps: inoculating a recombinant bacillus subtilis strain into a liquid culture medium for activation and amplification to obtain a seed solution; transferring the seed solution into a fermentation tank according to the inoculum size of 5%-10%, controlling the temperature to be 35-37 DEG C and the pH to be 6.8-7.2, introducing sterile air and stirring, and monitoring the thallus concentration OD600 value in real time; when the OD600 value reaches 35-38, 10% of an inducer is added for pre-induction; when the OD600 value reaches 40-45, the remaining 90% of the inducer is added for main induction, and the real-time dissolved oxygen value is collected; when the real-time dissolved oxygen value is continuously higher than a first preset threshold value, the flow acceleration rate of the inducer is increased, the fermentation temperature is increased at the same time or step by step, and the increase amplitude of the dissolved oxygen value is in positive correlation with the flow acceleration rate and the temperature increase amplitude; when the OD600 value is stabilized in a preset interval, it is judged that fermentation is completed, and the recombinant bacillus subtilis thalli are obtained. The yield and quality of the vibrio parahaemolyticus outer membrane protein can be effectively improved.

The invention relates to a bifunctional compound and application thereof in targeted degradation of protein, the compound comprises a target protein binding compound and a cell-penetrating peptide which are connected, and the target protein binding compound is a compound capable of binding with cell membrane protein or extracellular protein or a derivative thereof; the target protein binding compound and the cell-penetrating peptide are connected through a linker or directly connected. According to the invention, it is found for the first time that specific extracellular proteins or cell membrane proteins can enter cells in an endocytosis manner and are degraded through lysosomes by using cell-penetrating peptides and small molecule conjugates. The method disclosed by the invention has the characteristic of delivering bioactive macromolecules through endosome wrapping without depending on a single receptor, and the effect of degrading the target protein by using the cells can be realized as long as specific binding micromolecules of the protein to be degraded can be found and coupled with the cell-penetrating peptide; a widely applicable strategy is provided for degradation of extracellular proteins and cell membrane proteins.

The invention belongs to the technical field of functional nanoprobes and biological detection, and particularly relates to a kit for simultaneously detecting a specific membrane protein marker and a membrane protein dimer and application of the kit. The detection kit comprises a membrane proteome anchoring chain, a recognition probe, an SERS probe and an auxiliary signal amplification reagent, by combining DNA logic sensing based on aptamer recognition and logic response type assembly based on EpCAM protein expression and DNA signal amplification of Met protein dimerization, networked assembly of a recognition probe and an SERS probe is realized, so that specific accurate recognition of tumor cells and high-sensitivity SERS detection and imaging of membrane protein dimers are realized; the method is suitable for monitoring an HGF / Met signal channel based on Met protein dimerization mediation between stromal cells and cancer cells in a complex tumor microenvironment, and can evaluate the inhibition effect of a targeted drug on receptor dimerization in real time.

The invention discloses a hair follicle targeting nano-liposome anti-hair loss and hair growth compound preparation. The compound preparation is prepared from the following raw materials in parts by mass: 70 to 85 parts of bionic liposome carrier and 15 to 30 parts of active ingredients, the bionic liposome carrier is prepared from 50 to 60 parts of egg yolk lecithin, 15 to 20 parts of pH sensitive phospholipid DOPE, 10 to 15 parts of cholesterol and 5 to 10 parts of mesenchymal stem cell exosome membrane protein; the active ingredients comprise 5 to 10 parts of minoxidil, 3 to 5 parts of caffeine, 0.5 to 1 part of miR-218-5p, 1 to 2 parts of biotin and 2 to 3 parts of quercetin; the average particle size of the nano-liposome formed by the bionic liposome carrier is 120-180nm, and the polydispersity index (PDI) is less than or equal to 0.15. The invention relates to the technical field of biological medicines, in particular to a hair follicle-targeted nano-liposome anti-hair loss and hair growth compound preparation, which has the following advantages due to the adoption of the technical scheme: accurate targeted delivery is realized, and the treatment safety and accuracy are improved; intelligent response release is achieved, and the local microenvironment of hair follicles is optimized; the multi-target synergistic effect breaks through the limitation of single treatment.

The invention discloses an mRNA-LNPs Brucella vaccine, an expression vector and a preparation method thereof. The mRNA-LNPs Brucella vaccine comprises at least one of mRNA of an outer membrane protein BP26 and mRNA of an outer membrane protein Omp 25. According to the present invention, the antigen sequence is optimized, the prepared mRNA Brucella vaccine can stimulate the body to produce strong immunogenicity, and compared with the Brucella vaccine prepared before the sequence optimization, the antibody titer is significantly improved. A mouse immune experiment research result shows that high-titer IgG, IgG1 and IgG2a can be generated. Th1 type reaction, Th2 type reaction or mixed Th type reaction is successfully induced.

The invention discloses a mesenchymal stem cell membrane bionic nano-enzyme for targeted therapy of Parkinson's disease as well as a preparation method and application of the mesenchymal stem cell membrane bionic nano-enzyme. The mesenchymal stem cell membrane bionic nano enzyme comprises an inner core and a mesenchymal stem cell membrane, wherein the inner core is composed of mesoporous polydopamine nanoparticles, and the mesenchymal stem cell membrane coats the inner core. The medicine contains the mesenchymal stem cell membrane bionic nano enzyme. The mesenchymal stem cell membrane bionic nano-enzyme disclosed by the invention shows good biocompatibility, and can be homed to a Parkinson disease region in the brain under the mediation of CXCR4 and VLA-4 specific membrane proteins. In addition, through the CD47 membrane protein expressed on the surface, the removal of the immune system can be avoided, so that the action time in the body is prolonged. The nano-enzyme is helpful for eliminating reactive oxygen free radicals, reducing oxidative stress level and reducing damage of neuroinflammation to dopaminergic neurons, so that safe and efficient treatment of Parkinson's disease is realized.

The invention provides a recombinant chicken antibacterial peptide aiming at drug-resistant staphylococcus aureus, and belongs to the technical field of veterinarians. The recombinant chicken antibacterial peptide is expressed through genetic engineering recombinant escherichia coli. Three natural chicken antibacterial peptide active regions are fused, and two disulfide bonds are introduced to stabilize the structure of the recombinant chicken antibacterial peptide and enhance the affinity of the recombinant chicken antibacterial peptide to staphylococcus aureus outer membrane protein. The minimum inhibitory concentration of the recombinant chicken antibacterial peptide to the drug-resistant staphylococcus aureus is obviously lower than that of three natural chicken antibacterial peptides, and the formation of a biomembrane of a USA300 strain of the drug-resistant staphylococcus aureus can be thoroughly inhibited when the minimum inhibitory concentration is 8 mu g / mL. The recombinant chicken antibacterial peptide has a good antibacterial effect on different drug-resistant staphylococcus aureus separated from a chicken house, and can effectively solve the infection problem of the drug-resistant staphylococcus aureus in the chicken house.

The invention belongs to the technical field of genetic engineering, and particularly relates to a method for regulating and controlling production of human milk oligosaccharide through membrane protein. The method is realized by inactivating a membrane protein YgfX coding gene on a production strain. According to the human milk oligosaccharide production strain obtained in the mode that the membrane protein YgfX is inactivated after the coding gene of the membrane protein YgfX is knocked out or deleted from a 192nd guanine base through a gene editing technology, the human milk oligosaccharide production capacity of the human milk oligosaccharide production strain is obviously improved compared with that before gene editing, the yields of LNTII, LNnT, LNT, 3 '-SL and 6'-SL are improved by about 40%, 125%, 46%, 32% and 47% respectively, the effect is remarkable, and the human milk oligosaccharide production strain has a good application prospect. And a new method and thought are provided for widening the production way of the human milk oligosaccharide.

Provided herein are novel stabiligases for use in cell membrane proteome analysis. The subject stabiligases are capable of attaching to glycans found on the surface of cell membranes to form glycan-tethered (GT) stabiligases. Such glycan-tethered stabiligases are capable of robustly and selectively attaching label probes to cell surface proteins of intact cells. The subject novel stabiligases described herein advantageously allow for the identification and profiling of cell membrane proteins that have undergone an extracellular N-terminal proteolytic event.

The invention discloses an EV membrane protein single molecule detection method based on droplet microfluidics and application thereof. The method comprises the following steps: firstly, constructing an Ab-oligo compound which is formed by sequentially connecting an antibody, Linker, Linker connection DNA, RNA capable of being specifically cut by RNA enzyme and template DNA for starting signal amplification; then capturing the extracellular vesicles in the plasma by using the CD9 / CD63 / CD81 functionalized magnetic beads; the method comprises the following steps: adding an Ab-oligo compound and a sealing buffer solution into extracellular vesicles, incubating, removing the uncombined Ab-oligo compound, adding RNA enzyme for incubating and enzyme digestion, collecting template DNA for starting signal amplification, and performing microdroplet digital PCR analysis to realize single molecule analysis of EV membrane protein. According to the invention, the one-to-one correspondence relationship between the antibody and oligonucleotide is established through Linker for the first time, single protein information is converted into single nucleic acid chain information, and EV membrane protein single molecule detection is realized. The method is simple to operate, can qualitatively and quantitatively detect the single EV membrane protein, and is beneficial to further research on the relationship between the EV membrane protein and diseases.

The invention discloses a cell membrane protein replacement type oncolytic virus vector and application thereof. The cell membrane protein replacement type oncolytic virus vector is rhabdoviridae virus, and a nucleotide sequence for coding G protein in a genome of the rhabdoviridae virus is replaced by a nucleotide sequence for coding an antibody and a nucleotide sequence for coding a spike protein truncation of coronavirus. The invention also discloses a construction method of the cell membrane protein replacement type oncolytic virus vector for expressing the antibody, the non-replicated virus vector is used for expressing the antibody sequence for the first time, and meanwhile, the novel coronavirus cell membrane protein is embedded into the virus surface, so that the cell membrane protein replacement type oncolytic virus vector can be rapidly produced in a suspension cell in a large scale; through removal of virus cell membrane protein genes, the virus cell membrane protein genes cannot be continuously replicated in vivo, so that the safety of the virus cell membrane protein genes is ensured, the tumor immunosuppression condition is improved, and an organism can be stimulated to generate a neutralizing antibody for resisting new coronavirus while tumor cells are killed.

The invention belongs to the technical field of biological medicine, and particularly relates to an engineered cell microvesicle and a delivery system based on the engineered cell microvesicle, the system realizes efficient preparation of 1-5 [mu] m cell microvesicles, and the cell microvesicles have a large space volume and can be used for preparing the cell microvesicles. The carrier can be used for loading and delivery of target protein, polypeptide and recombinase which are specifically expressed in mother cells. The system transfects mother cells through lentivirus transfection or plasmid transfection to further produce cell microvesicles, and the microvesicles can load more goods and inherit membrane proteins of the mother cells, and can also effectively load intracellular proteins to realize effective delivery. By virtue of good structural stability, high immunogenicity and excellent biocompatibility, the cell microvesicle reduces systematic toxic and side effects of a traditional carrier, is expected to become an effective drug delivery system, and has great application potential in the field of gene therapy.

The invention discloses a separation-free and signal-amplification-free quantitative analysis method for extracellular vesicles, which comprises the following steps: assembling a sulfydryl-modified aptamer on the surface of a gold nanoparticle through an Au-S bond to form a gold nanoparticle-aptamer compound; the aptamer is designed according to a specific membrane protein receptor on an extracellular vesicle; incubating the gold nanoparticle-aptamer compound and an extracellular vesicle to-be-detected solution, and after incubation, specifically binding the gold nanoparticle-aptamer compound with EVs to form a large-particle compound; under laser irradiation, recording the Tyndall effect of the to-be-detected liquid by using a camera, and reading the Tyndall effect intensity value by using image analysis software.

The invention discloses a method for inducing osteoblasts by using mesenchymal stem cells, and belongs to the technical field of biology. The method for inducing the osteoblasts comprises the step of adding brucella outer membrane protein into a conventional osteoblast induction culture medium to promote the dental pulp stem cells to be differentiated into the osteoblasts. According to osteoblast differentiation metaphase differentiation marker detection, the cell ALP activity of a group added with 800ng / mL of brucella outer membrane protein is 2.36 times that of a conventional osteoblast induction culture medium group; according to osteoblast differentiation end-stage differentiation marker detection, the calcium deposition amount of brucella outer membrane proteome cells added with 800ng / mL is 481.54 mu g / mg protein, and is 2.55 times of that of a conventional osteoblast induction culture medium group. By adding the brucella outer membrane protein into a conventional osteoblast induction culture medium, the osteogenic differentiation efficiency of the dental pulp stem cells can be effectively improved.

Disclosed are fusion proteins (and homodimers and heterodimers thereof). Fusion proteins can bind to a protein of interest and to an internalizing receptor (transferrin receptor) on a cell surface. Once bound, the protein of interest can be internalized and / or degraded inside a cell.

The present invention relates to methods of preparing a therapeutic exosome using a protein newly-identified to be enriched on the surface of exosomes. Specifically, the present invention provides methods of using the proteins for affinity purification of exosomes. It also provides methods of localizing a therapeutic peptide on exosomes, and targeting exosomes to a specific organ, tissue or cell by using the proteins. The methods involve generation of surface-engineered exosomes that include one or more of the exosome proteins at higher density, or a variant or a fragment of the exosome protein.

The invention discloses a sheep paratuberculosis specific detection kit and application, and relates to the field of biological detection.The kit comprises an elisa plate coated with a recombinant Mycobacterium paratuberculosis membrane protein antigen, the nucleotide sequence of the recombinant Mycobacterium paratuberculosis membrane protein antigen is shown as SEQ ID NO: 1, and the amino acid sequence of the recombinant Mycobacterium paratuberculosis membrane protein antigen is shown as SEQ ID NO: 2; a confining liquid; a serum diluent; carrying out enzyme labeling on a second antibody; a TMB color developing solution and a stop solution; according to the sheep paratuberculosis specific detection kit disclosed by the invention, the recombinant Mycobacterium paratuberculosis membrane protein antigen is adopted as a core detection component, and the antigen has high specificity and can accurately identify paratuberculosis positive serum and effectively distinguish positive and negative samples; meanwhile, prokaryotic expression and purification are carried out on the specific membrane protein of the mycobacterium paratuberculosis for the first time, and a novel sheep paratuberculosis indirect ELISA diagnosis method with high sensitivity and specificity based on the protein as an antigen is established.

The invention relates to an mRNA (messenger Ribonucleic Acid) vaccine targeting FomA and application of the mRNA vaccine in immunotherapy of esophageal squamous carcinoma in the technical field of tumor immunotherapy. The problems that in the prior art, a specific targeting vaccine for the fusobacterium nucleatum membrane protein FomA lacks, traditional antibiotics can only kill extracellular bacteria and cannot remove intracellular colonized fusobacterium nucleatum, and cellular immunity cannot be effectively activated to remove fusobacterium nucleatum colonized in tumor tissue; the immunotherapy drug resistance of esophageal squamous carcinoma caused by fusobacterium nucleatum infection is difficult to reverse. According to the technical scheme, an mRNA molecule with a fusobacterium nucleatum FomA extracellular domain tandem repeat sequence and a lipid nanoparticle delivery system are coded, an extramembrane segment tandem repeat immune enhancement technology is adopted for design, two extracellular ring sequences are repeated for 2-5 times and connected through a connector sequence, lipid nanoparticles are composed of optimized quaternary lipids, and the lipid nanoparticles are prepared from the quaternary lipids. And a PD-1 monoclonal antibody is combined to activate FomA specific CD8 + T cell immunoreaction, so that comprehensive removal of intracellular and extracellular bacteria and bacteria targeted immune remodeling are realized.

The invention relates to a compound shown in a general formula I or a stereoisomer, a solvate, a hydrate, a prodrug, a stable isotope derivative and a pharmaceutically acceptable salt thereof. The compound can be anchored to the surface of a living cell through a hydrophobic acting force between a hydrophobic tail chain and a cell membrane and a receptor-ligand acting force between a ligand branch chain and cell membrane protein, the anchoring efficiency is high, the anchoring stability is high, and the treatment effect of the living cell on diseases can be enhanced; meanwhile, a biological orthogonal group can be introduced into the surface of a cell, and the cell anchored by the compound can be coupled with a nano-drug, a protein drug or a fluorescent probe and the like through a biological orthogonal reaction, so that the treatment effect on diseases can be remarkably improved, and in-vivo and in-vitro tracing of living cells can be realized. The compound shown in the general formula I provides a new technical platform for cell-based immune combination therapy, and provides a new thought and a new medicine for cell therapy based on various diseases. # imgabs0 #

The invention discloses a bionic nano-drug carrier of neutrophile granulocyte membrane fusion liposome as well as a preparation method and application of the bionic nano-drug carrier, and belongs to the field of medicines. The vector comprises a liposome and a neutrophile granulocyte membrane fused in the liposome, the liposome raw materials comprise DOPE, DPPC and cholesterol in a mass ratio of 6: 3: 1; the mass ratio of the liposome to the membrane protein is 1: 1. According to the method, a quantitative analysis strategy based on NanoFCM is established, and the fusion efficiency and fusion uniformity of NM (at) lipos can be accurately evaluated at the single particle level. The hybridization efficiency of the NM (at) lips (D) constructed on the basis of DOPE reaches 92.0% and is obviously higher than that of NM (at) lips (L) (70.1%) based on lecithin. In in-vivo experiments, the tumor enrichment capacity of NM (at) lipos (D) in 24 hours is improved by 5.1 times compared with that of Lipos (D), and the NM (at) lipos (D) shows remarkably prolonged circulation time.

The present application relates to specifically defined copolymers, a method for their preparation, a complex containing this copolymer, the use of the copolymer for solubilizing and stabilizing membrane proteins as well as a kit for this use containing the polymers according to the present invention.

The invention discloses a novel group B epidemic cerebrospinal meningitis outer membrane protein bifunctional vector, relates to the technical field of biopharmaceutical processes, and discloses a group B epidemic cerebrospinal meningitis outer membrane protein bifunctional vector and application thereof in epidemic cerebrospinal meningitis combined vaccinis.The bifunctional vector is human H factor binding protein fHbp and comprises two recombinant proteins BA and BB, the amino acid sequences of the amino acid sequences are respectively SEQ ID No. 62 and SEQ ID No. 63; the BA protein and the group A capsular polysaccharide are coupled to form a group A conjugate vaccine, the BB protein and the group C capsular polysaccharide are coupled to form a group C conjugate vaccine, the group A conjugate vaccine and the group C conjugate vaccine are mixed to form a group ABC triple vaccine, and each dose of the vaccine contains 40 micrograms of group A polysaccharide and 40 micrograms of group C polysaccharide, 160 micrograms of BA / BB protein and 1.0 mg of aluminum adjuvant; bA and BB proteins are expressed through escherichia coli and are subjected to high-pressure homogeneous crushing and anion exchange chromatography purification, and the purity is greater than or equal to 95%; the triple vaccine provided by the invention can simultaneously induce immune responses to group A, group B and group C meningococcal, the serum sterilization titer after first immunization is greater than or equal to 1: 32, and the titer after three immunization is maintained for more than 56 days.

The application discloses a kind of neutrophil membrane fusion liposome biomimetic nanomedicine carrier and its preparation method and application, belong to medical field.The carrier includes liposome and the neutrophil membrane fused to liposome;Liposome raw materials include DOPE, DPPC and cholesterol, and mass ratio is 6:3:1 in turn;Liposome and membrane protein mass ratio is 1:1.The application establishes quantitative analysis strategy based on NanoFCM, can accurately evaluate the fusion efficiency and fusion uniformity of NM@lipos at single particle level.Based on DOPE, the hybridization efficiency of NM@lipos (D) reaches 92.0%, which is significantly higher than that of NM@lipos (L) based on lecithin (70.1%).In in vivo experiment, the tumor enrichment capacity of NM@lipos (D) is increased by 5.1 times compared with Lipos (D) in 24 hours, and shows significantly prolonged circulation time.

The present invention relates to a method for separating and preparing milk fat globule membrane protein from buttermilk, a by-product of butter, comprising: controlling the temperature of the buttermilk, a by-product of butter, at 25 to 30 °C; adjusting the pH value to 4.5 to 4.7 and centrifuging; performing thermal calcium treatment and centrifuging; performing ultrasonic treatment and then cooling to room temperature; performing dialysis treatment; adjusting the pH value to 6-8, and then performing ultrafiltration treatment, and collecting the solution obtained by the ultrafiltration treatment as the milk fat globule membrane protein. The method of the present invention can increase the removal rate of casein to 95%, avoid the effective protein being dialyzed or filtered out, greatly reduce the loss rate of the milk fat globule membrane protein, make the extraction rate reach more than 70%, and the purity of the prepared milk fat globule membrane reaches 87.7%. Moreover, the raw material selected in the method of the present invention is buttermilk, a by-product of industrial butter production, which is usually discarded or made into animal feed. The present invention reasonably utilizes this raw material, which can not only improve the utilization rate of buttermilk, but also save costs.

The invention relates to the field of tumor immunotherapy, in particular to an mRNA vaccine targeting fusobacterium nucleatum membrane protein FomA and application of the mRNA vaccine in esophageal squamous cell carcinoma immunotherapy. The vaccine comprises a nucleotide sequence for coding a specific epitope of FomA, and the specific epitope contains 1-10'GGSGGGGSGG 'repetitive sequences and has homology gt in different strains; 95%. The mRNA is encapsulated in lipid nanoparticles (the particle size is 80-150 nm, the polydispersity coefficient is lt; and the liposome is composed of 38-42% of cationic lipid, 18-22% of neutral lipid, 33-37% of cholesterol and 3-5% of PEG modified lipid, and the encapsulation efficiency is 85-95%. The vaccine can specifically reduce the abundance of fusobacterium in tumors by 72.4 + / -8.0%, the tumor microenvironment is converted into an immune activation type, and the proportion of CD8 + T cells is increased from 5.2 + / -1.0% to 14.5 + / -2.0%. When the compound is combined with a PD-1 inhibitor, the objective remission rate reaches 70%, the tumor volume is reduced by 78.5 + / -8.0%, and the compound is suitable for treating clostridium-enriched esophageal squamous carcinoma.

The invention discloses a breast milk fat globule membrane protein simulation degree evaluation method based on multi-dimensional similarity weighted fusion, and the method comprises the steps: constructing a breast milk MFGM proteomics database, and obtaining the proteomics data of a to-be-evaluated sample; the method comprises the following steps: obtaining a reference matrix through row screening and column screening based on a breast milk MFGM proteomics database, performing logarithmic transformation on the reference matrix, calculating a mean value and a standard deviation of each feature in the reference matrix, and constructing a Z-score matrix and a missing mask matrix corresponding to the reference matrix; calculating abundance distribution similarity and missing mode similarity of the to-be-evaluated sample; setting a shrinkage coefficient based on the actual overlapping feature number, screening a core protein set according to a set threshold value, and comparing to obtain the missing MFGM protein type of the to-be-detected sample; and constructing a Top-K neighbor center, calculating the feature deviation contribution and abundance difference of the to-be-evaluated sample, and outputting key defect proteins and formula optimization suggestions according to preset feature importance indexes. And the similarity simulation accuracy is improved.

The invention relates to the technical field of biological detection, and particularly discloses an ELISA kit for detecting a neutralizing antibody of a severe fever with thrombocytopenia syndrome virus and an application method of the ELISA kit. The ELISA kit comprises an ELISA plate on which SFTSV receptor LRP1 protein is fixed, and an enzyme-labeled SFTSV Gn-8M, wherein the SFTSV receptor LRP1 protein is fixed on the ELISA plate; the SFTSV Gn-8M is an SFTSV membrane protein Gn mutant designed by the invention, and can be specifically combined with an SFTSV receptor LRP1 protein on an elisa plate, and compared with a standard virus strain Gn protein, the self-designed SFTSV Gn-8M has amino acid mutation of eight sites, has stronger combining capacity with a host cell receptor, and can be used for detecting the SFTSV. The kit disclosed by the invention has the characteristics of high safety, high efficiency, high flux, high specificity, high sensitivity, high stability and the like, and is suitable for large-scale rapid screening of the neutralizing antibody of the severe fever with thrombocytopenia syndrome virus.

The present invention relates to anti-ILT7 antibodies. Antibodies capable of binding to IPC are obtained by using animal cells in which a cell membrane protein that binds to ILT7 is co-expressed as an immunogen. The antibodies of the present invention have high specificity, such that the antibodies can immunologically distinguish ILT7 from other ILT family molecules. The anti-ILT-7 antibodies of the present invention can bind to IPC and inhibit its activity. The activity of IPC can be inhibited by the anti-ILT-7 antibodies of the present invention, and interferon-related diseases can be treated or prevented. In the presence of IFNα, the expression of ILT7 in IPC can still be maintained. Therefore, in patients with various autoimmune diseases with increased IFNα production, an inhibitory effect of anti-ILT-7 antibodies on the activity of IPC can be expected.

This invention discloses a biodegradable brush-shaped polymer drug carrier and its applications, belonging to the field of polymer compound technology. The brush-shaped polymer drug carrier is obtained by a click reaction between a polydisulfide backbone and cationic side chains. The polydisulfide backbone in its structure can undergo a special "sulfhydryl exchange" reaction with free thiol groups present on cell membrane proteins, directly carrying the nucleic acid drug into the cell through the cell membrane, thus completing the delivery of the nucleic acid drug. After entering the body, under the action of glutathione (GSH) which is abundant in the tumor cell cytoplasm, the polydisulfide backbone is broken and degraded, releasing the nucleic acid drug, which is suitable for the delivery of nucleic acid drugs.